Status:
RECRUITING
Prevelence of Liver Disease-Related Outcomes in People With HIV
Lead Sponsor:
Shanghai Public Health Clinical Center
Conditions:
MAFLD
Liver Fibrosis
Eligibility:
All Genders
18-70 years
Brief Summary
Antiretroviral therapy can effectively control the replication of HIV, prolong the lifespan of patients infected with HIV, and improve their quality of life.At the same time, non-AIDS-related diseases...
Detailed Description
Chronic liver injury caused by various etiologies can lead to liver fibrosis. Liver fibrosis refers to the imbalance between the synthesis and degradation of extracellular matrix in the liver under th...
Eligibility Criteria
Inclusion
- Aged between 18 and 70 years old
- HIV positive individuls
- Had abdominal ultrasound and Fibroscan done between December 2019 and April 2020, with available data of LSM and CAP, and had routine follow - up at our hospital's outpatient department from April 2020 to April 2025.
Exclusion
- Men with excessive alcohol consumption (more than 210g/week) and women with excessive alcohol consumption (more than 140g/week).
- Suffering from other liver diseases, such as viral hepatitis, drug-induced liver disease, autoimmune liver disease, decompensated liver cirrhosis, liver malignancy, or having had a liver transplantation.
- Pregnant women and lactating women.
Key Trial Info
Start Date :
July 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT06940375
Start Date
July 1 2025
End Date
February 1 2026
Last Update
December 30 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China, 201508
2
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China, 201508